Venture building has a perception problem. Across much of the Western innovation ecosystem, the term often invites scepticism — linked to failed corporate initiatives, consultant-led “startup factories,” and accelerators that never quite delivered. The prevailing view is that venture building is slow, rigid, and ill-equipped to compete with lean, independent founders.
But that narrative may be incomplete.
What if some of Europe’s most defensible deep-tech companies don’t emerge despite large corporates — but because ofthem?
In this episode of 0100 Impact Talks, I spoke with Axel Deniz, CEO of Bosch Business Innovation, to discuss how Bosch approaches venture building differently — and why corporate venture creation may be entering a more mature, disciplined, and increasingly essential phase for deep-tech innovation.
As private equity adapts to a prolonged high-cost environment, investors are being forced to rethink how they source deals, create value, and deploy capital. Ahead of her appearance at 0100 Europe (April 21–23), we spoke with Geraldine O’Keeffe, Partner at EQT Healthcare Growth, about how one of Europe’s leading investment platforms is transiting today’s market dynamics—across healthcare, technology, and beyond.
